Daratumumab for heavily pretreated multiple myeloma - European Medical Journal

Daratumumab for heavily pretreated multiple myeloma

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses the anti-CD38 monoclonal antibody, daratumumab, for the treatment of patients with pretreated multiple myeloma.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?